KRAS and non-small cell lung carcinoma: Karatrasoglou et al. highlighted that PD-L1 positive (TPS ≥ 1%) NSCLC patients showed a concomitant KRAS mutation, and in particular KRAS exon 2 p,G12C point mutation, in a higher percentage of patients with respect to PD-L1 negative patients [36].